GENERAL ASSEMBLY OF NORTH CAROLINA

SESSION 2017

S                                                                                                                                                     1

SENATE BILL 347*

 

 

Short Title:      Revise Schedule of Controlled Substances.

(Public)

Sponsors:

Senators J. Davis, McInnis (Primary Sponsors);  and Rabin.

Referred to:

Rules and Operations of the Senate

March 22, 2017

A BILL TO BE ENTITLED

AN ACT revising the schedule of controlled substances to add synthetic fentanyls, designer hallucinogenics, synthetic cannabinoids, system depressants, and other substances.

The General Assembly of North Carolina enacts:

SECTION 1.  This act shall be known and may be cited as the "Synthetic Opioid and Other Dangerous Drug Control Act."

SECTION 2.  G.S. 90‑89 reads as rewritten:

"§ 90‑89.  Schedule I controlled substances.

This schedule includes the controlled substances listed or to be listed by whatever official name, common or usual name, chemical name, or trade name designated. In determining that a substance comes within this schedule, the Commission shall find: a high potential for abuse, no currently accepted medical use in the United States, or a lack of accepted safety for use in treatment under medical supervision. The following controlled substances are included in this schedule:

(1)        Opiates. – Any of the following opiates, including the isomers, esters, ethers, salts and salts of isomers, esters, and ethers, unless specifically excepted, or listed in another schedule, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation:

a.         Acetyl‑alpha‑methylfentanyl (N[1‑(1‑methyl‑2‑phenethyl)‑4/y‑piperidinyl]‑N‑phenylacet amide).

b.         Acetylmethadol.

c.         Repealed by Session Laws 1987, c. 412, s. 2.

d.         Alpha‑methylthiofentanyl (N‑[1‑methyl‑2‑(2‑thienyl)ethyl/y‑4/y‑piperidinyl]‑N‑phenylpropanamide).

e.         Allylprodine.

f.          Alphacetylmethadol.

g.         Alphameprodine.

h.         Alphamethadol.

i.          Alpha‑methylfentanyl (N‑(1‑(alpha‑methyl‑beta‑phenyl) ethyl‑4‑piperidyl) propionalilide; 1(1‑methyl‑2‑phenyl‑ethyl)‑4‑(N‑propanilido) piperidine).

j.          Benzethidine.

k.         Betacetylmethadol.

l.          Beta‑hydroxfentanyl (N‑[1‑(2‑hydroxy‑2‑phenethyl)‑4‑piperidinyl]‑N‑phenylpropanamide).

m.        Beta‑hydroxy‑3‑methylfentanyl (N‑[1‑(2‑hydroxy‑2‑phenethyl)‑3‑methyl‑4‑piperidinyl]‑N‑pheny lpropanamide).

n.         Betameprodine.

o.         Betamethadol.

p.         Betaprodine.

q.         Clonitazene.

r.          Dextromoramide.

s.          Diampromide.

t.          Diethylthiambutene.

u.         Difenoxin.

v.         Dimenoxadol.

w.        Dimepheptanol.

x.         Dimethylthiambutene.

y.         Dioxaphetyl butyrate.

z.         Dipipanone.

aa.        Ethylmethylthiambutene.

bb.       Etonitazene.

cc.        Etoxeridine.

dd.       Furethidine.

ee.        Hydroxypethidine.

ff.        Ketobemidone.

gg.       Levomoramide.

hh.       Levophenacylmorphan.

ii.         1‑methyl‑4‑phenyl‑4‑propionoxypiperidine (MPPP).

jj.         3‑Methylfentanyl (N‑[3‑methyl‑1‑(2‑Phenylethyl)‑4‑Pi‑ peridyl]‑N‑Phenylpropanamide).

kk.       3‑Methylthiofentanyl (N‑[(3‑methyl‑1‑(2‑thienyl)ethyl/y‑4‑piperidinyl]‑N‑phenylpropanamide).

ll.         Morpheridine.

mm.     Noracymethadol.

nn.       Norlevorphanol.

oo.       Normethadone.

pp.       Norpipanone.

qq.       Para‑fluorofentanyl (N‑(4‑fluorophenyl)‑N‑[1‑(2‑phen‑ethyl)‑4‑piperidinyl]‑pr   opanamide.

rr.         Phenadoxone.

ss.        Phenampromide.

tt.         1‑(2‑phenethyl)‑4‑phenyl‑4‑acetoxypiperidine (PEPAP).

uu.       Phenomorphan.

vv.       Phenoperidine.

ww.     Piritramide.

xx.       Proheptazine.

yy.       Properidine.

zz.        Propiram.

aaa.      Racemoramide.

bbb.     Thiofentanyl (N‑phenyl‑N‑[1‑(2‑thienyl)ethyl‑4‑piperidinyl]‑propanamide.

ccc.      Tilidine.

ddd.    Trimeperidine.

eee.      Acetyl Fentanyl.

fff.       Trans‑3,4‑dichloro‑N‑(2(dimethylamino)cyclohexyl)‑N‑methyl-benzamide (U47700).

(1a)      Fentanyl Derivatives. – Any compounds derived from N‑[1‑(2‑phenylethyl)‑4‑piperidinyl]‑N‑phenylpropanamide (Fentanyl) by any substitution on or replacement of the phenethyl group, any substitution on the piperidine ring, any substitution on or replacement of the propanamide group, any substitution on the anilido phenyl group, or any combination of the above unless specifically excepted or listed in another schedule to include their salts, isomers, and salts of isomers. Fentanyl derivatives include, but are not limited to, the following:

a.         N‑(1‑phenylethylpiperidin‑4‑yl)‑N‑phenylfuran‑2‑carboxamide (also known as Furanyl Fentanyl).

b.         N‑(1‑phenethylpiperidin‑4‑yl)‑N‑phenylbutyramide; N‑(1‑phenethylpiperidin‑4‑yl)‑N‑phenylbutanamide (also known as Butyryl Fentanyl).

c.         N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropionamide;

N‑[1‑[2‑hydroxy‑2‑(2‑thienyl)ethyl]‑4‑piperidinyl]‑N‑phenylpropanamide (also known as Beta‑Hydroxythiofentanyl).

d.         N‑phenyl‑N‑[1‑(2‑phenylethyl)piperidin‑4‑yl]‑2propenamide (also known as Acrylfentanyl).

e.         N‑phenyl‑N‑[1‑(2‑phenylethyl)‑4‑piperidinyl]‑pentanamide (also known as Valeryl Fentanyl).

f.          N-(2-fluorophenyl)-N-[1-(2-phenylethyl)-4-piperidinyl]-propanamide (also known as 2-fluorofentanyl).

g.         N‑(3‑fluorophenyl)‑N‑[1‑(2‑phenylethyl)‑4‑piperidinyl]-propanamide (also known as 3-fluorofentanyl).

h.         N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide (also known as tetrahydrofuran fentanyl).

i.          N-(4-fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)-4-piperidinyl]-propanamide (also known as 4-fluoroisobutyryl fentanyl, 4-FIBF).

j.          N-(4-fluorophenyl)-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide (also known as 4‑fluorobutyryl fentanyl, 4‑FBF).

(2)        Opium Derivatives. – Any of the following opium derivatives, including their salts, isomers, and salts of isomers, unless specifically excepted, or listed in another schedule, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

a.         Acetorphine.

b.         Acetyldihydrocodeine.

c.         Benzylmorphine.

d.         Codeine methylbromide.

e.         Codeine‑N‑Oxide.

f.          Cyprenorphine.

g.         Desomorphine.

h.         Dihydromorphine.

i.          Etorphine (except hydrochloride salt).

j.          Heroin.

k.         Hydromorphinol.

l.          Methyldesorphine.

m.        Methyldihydromorphine.

n.         Morphine methylbromide.

o.         Morphine methylsulfonate.

p.         Morphine‑N‑Oxide.

q.         Myrophine.

r.          Nicocodeine.

s.          Nicomorphine.

t.          Normorphine.

u.         Pholcodine.

v.         Thebacon.

w.        Drotebanol.

(3)        Hallucinogenic Substances. – Any material, compound, mixture, or preparation which contains any quantity of the following hallucinogenic substances, including their salts, isomers, and salts of isomers, unless specifically excepted, or listed in another schedule, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

a.         3, 4‑methylenedioxyamphetamine.

b.         5‑methoxy‑3, 4‑methylenedioxyamphetamine.

c.         3, 4‑Methylenedioxymethamphetamine (MDMA).

d.         3,4‑methylenedioxy‑N‑ethylamphetamine (also known as N‑ethyl‑alpha‑methyl‑3,4‑(methylenedioxy)phenethylamine, N‑ethyl MDA, MDE, and MDEA).

e.         N‑hydroxy‑3,4‑methylenedioxyamphetamine (also known as N‑hydroxy/y‑alpha‑methyl‑3,4‑(methylenedioxy)phenethylamine, and N‑hydroxy MDA).

f.          3, 4, 5‑trimethoxyamphetamine.

g.         Alpha‑ethyltryptamine. Some trade or other names: etryptamine, Monase, alpha‑ethyl‑1H‑indole‑3‑ ethanamine, 3‑(2‑aminobutyl) indole, alpha‑ET, and AET.

h.         Bufotenine.

i.          Diethyltryptamine.

j.          Dimethyltryptamine.

k.         4‑methyl‑2, 5‑dimethoxyamphetamine.

l.          Ibogaine.

m.        Lysergic acid diethylamide.

n.         Mescaline.

o.         Peyote, meaning all parts of the plant presently classified botanically as Lophophora Williamsii Lemaire, whether growing or not; the seeds thereof; any extract from any part of such plant; and every compound, manufacture, salt, derivative, mixture or preparation of such plant, its seed or extracts.

p.         N‑ethyl‑3‑piperidyl benzilate.

q.         N‑methyl‑3‑piperidyl benzilate.

r.          Psilocybin.

s.          Psilocin.

t.          2, 5‑dimethoxyamphetamine.

u.         2, 5‑dimethoxy‑4‑ethylamphetamine. Some trade or other names: DOET.

v.         4‑bromo‑2, 5‑dimethoxyamphetamine.

w.        4‑methoxyamphetamine.

x.         Ethylamine analog of phencyclidine. Some trade or other names: N‑ethyl‑1‑phenylcyclohexylamine, (1‑phenylcyclohexyl) ethylamine, N‑(1‑phenylcyclohexyl) ethylamine, cyclohexamine, PCE.

y.         Pyrrolidine analog of phencyclidine. Some trade or other names: 1‑(1‑phenylcyclohexyl)‑pyrrolidine, PCPy, PHP.

z.         Thiophene analog of phencyclidine. Some trade or other names: 1‑[1‑(2‑thienyl)‑cyclohexyl]‑piperidine, 2‑thienyl analog of phencyclidine, TPCP, TCP.

aa.        1‑[1‑(2‑thienyl)cyclohexyl]pyrrolidine; Some other names: TCPy.

bb.       Parahexyl.

cc.        4‑Bromo‑2, 5‑Dimethoxyphenethylamine.

dd.       Alpha‑Methyltryptamine.

ee.        5‑Methoxy‑n‑diisopropyltryptamine.

ff.        Methoxetamine (other names: MXE, 3‑MeO‑2‑Oxo‑PCE).

gg.       BTCP (Benzothiophenylcyclohexylpiperidine).

hh.       Deschloroketamine.

jj.         3‑MeO‑PCP (3‑methoxyphencyclidine).

kk.       4‑hydroxy‑MET.

ll.         4‑OH‑MiPT (4‑hydroxy‑N‑methyl‑N‑isopropyltryptamine).

mm.     5‑methoxy‑N‑methyl‑N‑propyltryptamine (5‑MeO‑MiPT).

(4)        Systemic Depressants. – Any material compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation, unless specifically excepted or unless listed in another schedule:

a.         Mecloqualone.

b.         Methaqualone.

c.         Gamma hydroxybutyric acid; Some other names: GHB, gamma‑hydroxybutyrate, 4‑hydroxybutyrate, 4‑hydroxybutanoic acid; sodium oxybate; sodium oxybutyrate.

d.         Etizolam.

e.         Flubromazepam.

(5)        Stimulants. – Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:

a.         Aminorex. Some trade or other names: aminoxaphen; 2‑amino‑5‑phenyl‑2‑oxazoline; or 4,5‑dihydro‑5‑phenyl‑2‑oxazolamine.

b.         Cathinone. Some trade or other names: 2‑amino‑1‑phenyl‑1‑propanone, alpha‑aminopropiophenone, 2‑aminopropiophenone, and norephedrone.

c.         Fenethylline.

d.         Methcathinone. Some trade or other names: 2‑(methylamino)‑ propiophenone, alpha‑(methylamino)propiophenone, 2‑(methy‑ lamino)‑1‑phenylpropan‑1‑one, alpha‑N‑methylamino‑ propiophenone, monomethylproprion, ephedrone, N‑methylcathinone, methylcathinone, AL‑464, AL‑422, AL‑463, and UR1432.

e.         (+‑)cis‑4‑methylaminorex [(+‑)cis‑4,5‑dihydro‑4‑methyl‑5‑phenyl‑2‑oxazolamine] (also known as 2‑amino‑4‑methyl‑5‑phenyl‑2‑oxazoline).

f.          N,N‑dimethylamphetamine. Some other names: N,N,alpha‑tri‑ methylbenzeneethaneamine; N,N,alpha‑trimethylphenethylamine.

g.         N‑ethylamphetamine.

h.         4‑methylmethcathinone (also known as mephedrone).

i.          3,4‑Methylenedioxypyrovalerone (also known as MDPV).

j.          A compound, other than bupropion, that is structurally derived from 2‑amino‑1‑phenyl‑1‑propanone by modification in any of the following ways: (i) by substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl, or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents; (ii) by substitution at the 3‑position with an alkyl substituent; or (iii) by substitution at the nitrogen atom with alkyl or dialkyl groups or by inclusion of the nitrogen atom in a cyclic structure.

k.         N‑Benzylpiperazine.

l.          2,5 – Dimethoxy‑4‑(n)‑propylthiophenethylamine.

(6)        NBOMe Compounds. – Any material compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation unless specifically excepted or unless listed in another schedule:

a.         25B‑NBOMe (2C‑B‑NBOMe)‑2‑(4‑Bromo‑2,5‑dimethoxyphenyl)‑N‑(2‑methoxybenzyl)ethanamine.

b.         25C‑NBOMe (2C‑C‑NBOMe)‑2‑(4‑Chloro‑2,5‑dimethoxyphenyl)‑N‑(2‑methoxybenzyl)ethanamine.

c.         25D‑NBOMe (2C‑D‑NBOMe)‑2‑(2,5‑dimethoxy‑4‑methylphenyl)‑N‑(2‑methoxybenzyl)ethanamine.

d.         25E‑NBOMe (2C‑E‑NBOMe)‑2‑(4‑Ethyl‑2,5‑dimethoxyphenyl)‑N‑(2‑methoxybenzyl)ethanamine.

e.         25G‑NBOMe (2C‑G‑NBOMe)‑2‑(2,5‑dimethoxy‑3,4‑dimethylphenyl)‑N‑(2‑methoxybenzyl)ethanamine.

f.          25H‑NBOMe (2C‑H‑NBOMe)‑2‑(2,5‑dimethoxyphenyl)‑N‑(2‑methoxybenzyl)ethanamine.

g.         25I‑NBOMe (2C‑I‑NBOMe)‑2‑(4‑Iodo‑2,5‑dimethoxyphenyl)‑N‑(2‑methoxybenzyl)ethanamine.

h.         25N‑NBOMe (2C‑N‑NBOMe)‑2‑(2,5‑dimethoxy‑4‑nitrophenyl)‑N‑(2‑methoxybenzyl)ethanamine.

i.          25P‑NBOMe (2C‑P‑NBOMe)‑2‑(4‑Propyl‑2,5‑dimethoxyphenyl)‑N‑(2‑methoxybenzyl)ethanamine.

j.          25T2‑NBOMe (2C‑T2‑NBOMe)‑2,5‑dimethoxy‑N‑[(2‑methoxyphenyl)methyl]‑4‑(methylthio)‑benzeneethanamine.

k.         25T4‑NBOMe (2C‑T4‑NBOMe)‑2,5‑dimethoxy‑N‑[(2‑methoxyphenyl)methyl]‑4‑[(1‑methylethyl)thio]‑benzeneethanamine.

l.          25T7‑NBOMe (2C‑T7‑NBOMe)‑2,5‑dimethoxy‑N‑[(2‑methoxyphenyl)methyl]‑4‑(propylthio)‑benzeneethanamine."

(7)        Synthetic Cannabinoids. – Any quantity of any synthetic chemical compound that (i) is a cannabinoid receptor agonist and mimics the pharmacological effect of naturally occurring substances or (ii) has a stimulant, depressant, or hallucinogenic effect on the central nervous system that is not listed as a controlled substance in Schedule I through V, and is not an FDA‑approved drug. Synthetic cannabinoids include, but are not limited to, the substances listed in sub‑subdivisions a. through p. of this subdivision and any substance that contains any quantity of their salts, isomers (whether optical, positional, or geometric), homologues, and salts of isomers and homologues, unless specifically excepted, whenever the existence of these salts, isomers, homologues, and salts of isomers and homologues is possible within the specific chemical designation. The following substances are examples of synthetic cannabinoids and are not intended to be inclusive of the substances included in this Schedule:

a.         Naphthoylindoles. Any compound containing a 3‑(1‑naphthoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1‑(N‑methyl‑2‑piperidinyl)methyl, or 2‑(4‑morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent. Some trade or other names: JWH‑015, JWH‑018, JWH‑019, JWH‑073, JWH‑081, JWH‑122, JWH‑200, JWH‑210, JWH‑398, AM‑2201, and WIN 55‑212.

b.         Naphthylmethylindoles. Any compound containing a 1H‑indol‑3‑yl‑(1‑naphthyl)methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1‑(N‑methyl‑2‑piperidinyl)methyl, or 2‑(4‑morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent.

c.         Naphthoylpyrroles. Any compound containing a 3‑(1‑naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1‑(N‑methyl‑2‑piperidinyl)methyl, or 2‑(4‑morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent. Another name: JWH‑307.

d.         Naphthylmethylindenes. Any compound containing a naphthylideneindene structure with substitution at the 3‑position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1‑(N‑methyl‑2‑piperidinyl)methyl, or 2‑(4‑morpholinyl)ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent.

e.         Phenylacetylindoles. Any compound containing a 3‑phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1‑(N‑methyl‑2‑piperidinyl)methyl, or 2‑(4‑morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. Some trade or other names: SR‑18, RCS‑8, JWH‑250, and JWH‑203.

f.          Cyclohexylphenols. Any compound containing a 2‑(3‑hydroxycyclohexyl)phenol structure with substitution at the 5‑position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1‑(N‑methyl‑2‑piperidinyl)methyl, or 2‑(4‑morpholinyl)ethyl group, whether or not substituted in the cyclohexyl ring to any extent. Some trade or other names: CP 47,497 (and homologues), cannabicyclohexanol.

g.         Benzoylindoles. Any compound containing a 3‑(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1‑(N‑methyl‑2‑piperidinyl)methyl, or 2‑(4‑morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. Some trade or other names: AM‑694, Pravadoline (WIN 48,098), and RCS‑4.

h.         2,3‑Dihydro‑5‑methyl‑3‑(4‑morpholinylmethyl)pyrrolo[1,2,3‑de]‑1, 4‑benzoxazin‑6‑yl]‑1‑napthalenylmethanone. Some trade or other names: WIN 55,212‑2.

i.          (6aR,10aR)‑9‑(hydroxymethyl)‑6, 6‑dimethyl‑3‑(2‑methyloctan‑2‑yl) – 6a,7,10,10a‑tetrahydrobenzo[c]chromen‑1‑ol 7370. Some trade or other names: HU‑210.

j.          3‑(cyclopropylmethanone) indole or 3‑(cyclobutylmethanone) indole or 3‑(cyclopentylmethanone) indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not further substituted on the cyclopropyl, cyclobutyl, or cyclopentyl rings to any extent. Substances in this class include, but are not limited to: UR‑144, fluoro‑UR‑144, XLR‑11, A‑796,260, and A‑834,735.

k.         Indole carboxaldehydes. Any compound structurally derived from 1H‑indole‑3‑carboxaldehyde or 1H‑indole‑2‑carboxaldehyde substituted in both of the following ways:

1.         At the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1‑(N‑methyl‑2‑piperidinyl)methyl, 2‑(4‑morpholinyl)ethyl, 1‑(N‑methyl‑2‑pyrrolidinyl)methyl, 1‑(N‑methyl‑3‑morpholinyl)methyl, tetrahydropyranylmethyl, benzyl, or halo benzyl group; and

2.         At the carbon of the carboxaldehyde by a phenyl, benzyl, naphthyl, adamantyl, cyclopropyl, or propionaldehyde group;

            whether or not the compound is further modified to any extent in the following ways: (i) substitution to the indole ring to any extent, (ii) substitution to the phenyl, benzyl, naphthyl, adamantyl, cyclopropyl, or propionaldehyde group to any extent, (iii) a nitrogen heterocyclic analog of the indole ring, or (iv) anitrogen heterocyclic analog of the phenyl, benzyl, naphthyl, adamantyl, or cyclopropyl ring. Substances in this class include but are not limited to: AB‑001.

l.          Indole carboxamides. Any compound structurally derived from 1H‑indole‑3‑carboxamide or 1H‑indole‑2‑carboxamide substituted in both of the following ways:

1.         At the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1‑(N‑methyl‑2‑piperidinyl)methyl, 2‑(4‑morpholinyl)ethyl, 1‑(N‑methyl‑2‑pyrrolidinyl)methyl, 1‑(N‑methyl‑3‑morpholinyl)methyl, tetrahydropyranylmethyl, benzyl, or halo benzyl group; and

2.         At the nitrogen of the carboxamide by a phenyl, benzyl,   naphthyl, adamantyl, cyclopropyl, or propionaldehyde group;

            whether or not the compound is further modified to any extent in the following ways: (i) substitution to the indole ring to any extent, (ii) substitution to the phenyl, benzyl, naphthyl, adamantyl, cyclopropyl, or propionaldehyde group to any extent, (iii) a nitrogen heterocyclic analog of the indole ring, or (iv) a nitrogen heterocyclic analog of the phenyl, benzyl, naphthyl, adamantyl, or cyclopropyl ring. Substances in this class include, but are not limited to: SDB‑001 and STS‑135.

m.        Indole carboxylic acids. Any compound structurally derived from 1H‑indole‑3‑carboxylic acid or 1H‑indole‑2‑carboxylic acid substituted in both of the following ways:

1.         At the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1‑(N‑methyl‑2‑piperidinyl)methyl, 2‑(4‑morpholinyl)ethyl, 1‑(N‑methyl‑2‑pyrrolidinyl)methyl, 1‑(N‑methyl‑3‑morpholinyl)methyl, tetrahydropyranylmethyl, benzyl, or halo benzyl group; and

2.         At the nitrogen of the carboxamide by a phenyl, benzyl,   naphthyl, adamantyl, cyclopropyl, or propionaldehyde group;

            whether or not the compound is further modified to any extent in the following ways: (i) substitution to the indole ring to any extent, (ii) substitution to the phenyl, benzyl, naphthyl, adamantyl, cyclopropyl, or propionaldehyde group to any extent, (iii) a nitrogen heterocyclic analog of the indole ring, or (iv) a nitrogen heterocyclic analog of the phenyl, benzyl, naphthyl, adamantyl, or cyclopropyl ring. Substances in this class include, but are not limited to: SDB‑001 and STS‑135.

whether or not the compound is further modified to any extent in the following ways: (i) substitution to the indole ring to any extent, (ii) substitution to the phenyl, benzyl, naphthyl, adamantyl, cyclopropyl, or propionaldehyde group to any extent, (iii) a nitrogen heterocyclic analog of the indole ring, or (iv) a nitrogen heterocyclic analog of the phenyl, benzyl, naphthyl, adamantyl, or cyclopropyl ring. Substances in this class include, but are not limited to: PB‑22 and fluoro‑PB‑22.

n.         Indazole carboxaldehydes. Any compound structurally derived from 1H‑indazole‑3‑carboxaldehyde or 1H‑indazole‑2‑carboxaldehyde substituted in both of the following ways:

1.         At the nitrogen atom of the indazole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1‑(N‑methyl‑2‑piperidinyl)methyl, 2‑(4‑morpholinyl)ethyl, 1‑(N‑methyl‑2‑pyrrolidinyl)methyl, 1‑(N‑methyl‑3‑morpholinyl)methyl, tetrahydropyranylmethyl, benzyl, or halo benzyl group; and

2.         At the carbon of the carboxaldehyde by a phenyl, benzyl,

            whether or not the compound is further modified to any extent in the following ways: (i) substitution to the indazole ring to any extent, (ii) substitution to the phenyl, benzyl, naphthyl, adamantyl, cyclopropyl, or propionaldehyde group to any extent, (iii) a nitrogen heterocyclic analog of the indazole ring, or (iv) a nitrogen heterocyclic analog of the phenyl, benzyl, naphthyl, adamantyl, or cyclopropyl ring.

o.         Indazole carboxamides. Any compound structurally derived from 1H‑indazole‑3‑carboxamide or 1H‑indazole‑2‑carboxamide substituted in both of the following ways:

1.         At the nitrogen atom of the indazole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1‑(N‑methyl‑2‑piperidinyl)methyl, 2‑(4‑morpholinyl)ethyl, 1‑(N‑methyl‑2‑pyrrolidinyl)methyl, 1‑(N‑methyl‑3‑morpholinyl)methyl, tetrahydropyranylmethyl, benzyl, or halo benzyl group; and

2.         At the nitrogen of the carboxamide by a phenyl, benzyl, naphthyl, adamantyl, cyclopropyl, or propionaldehyde group;

            whether or not the compound is further modified to any extent in the following ways: (i) substitution to the indazole ring to any extent, (ii) substitution to the phenyl, benzyl, naphthyl, adamantyl, cyclopropyl, or propionaldehyde group to any extent, (iii) a nitrogen heterocyclic analog of the indazole ring, or (iv) a nitrogen heterocyclic analog of the phenyl, benzyl, naphthyl, adamantyl, or cyclopropyl ring. Substances in this class include, but are not limited to: AKB‑48, fluoro‑AKB‑48, APINCACA, AB‑PINACA, AB‑FUBINACA, ADB‑FUBINACA, and ADB‑PINACA.

p.         Indazole carboxylic acids. Any compound structurally derived from 1H‑indazole‑3‑carboxylic acid or 1H‑indazole‑2‑carboxylic acid substituted in both of the following ways:

1.         At the nitrogen atom of the indazole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1‑(N‑methyl‑2‑piperidinyl)methyl, 2‑(4‑morpholinyl)ethyl, 1‑(N‑methyl‑2‑pyrrolidinyl)methyl, 1‑(N‑methyl‑3‑morpholinyl)methyl, tetrahydropyranylmethyl, benzyl, or halo benzyl group; and

2.         At the hydroxyl group of the carboxylic acid by a phenyl, benzyl, naphthyl, adamantyl, cyclopropyl, or propionaldehyde group;

            whether or not the compound is further modified to any extent in the following ways: (i) substitution to the indazole ring to any extent, (ii) substitution to the phenyl, benzyl, naphthyl, adamantyl, cyclopropyl, or propionaldehyde group to any extent, (iii) a nitrogen heterocyclic analog of the indazole ring, or (iv) a nitrogen heterocyclic analog of the phenyl, benzyl, naphthyl, adamantyl, or cyclopropyl ring."

SECTION 3.  G.S. 90‑90 reads as rewritten:

"§ 90‑90.  Schedule II controlled substances.

This schedule includes the controlled substances listed or to be listed by whatever official name, common or usual name, chemical name, or trade name designated. In determining that a substance comes within this schedule, the Commission shall find: a high potential for abuse; currently accepted medical use in the United States, or currently accepted medical use with severe restrictions; and the abuse of the substance may lead to severe psychic or physical dependence. The following controlled substances are included in this schedule:

(1)        Any of the following substances whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis, unless specifically excepted or unless listed in another schedule:

a.         Opium and opiate, and any salt, compound, derivative, or preparation of opium and opiate, excluding apomorphine, nalbuphine, dextrorphan, naloxone, naltrexone and nalmefene, and their respective salts, but including the following:

1.         Raw opium.

2.         Opium extracts.

3.         Opium fluid extracts.

4.         Powdered opium.

5.         Granulated opium.

6.         Tincture of opium.

7.         Codeine.

8.         Ethylmorphine.

9.         Etorphine hydrochloride.

10.       Hydrocodone. Any material, compound, mixture, or preparation which contains any quantity of hydrocodone.

11.       Hydromorphone.

12.       Metopon.

13.       Morphine.

14.       Oxycodone.

15.       Oxymorphone.

16.       Thebaine.

17.       Dihydroetorphine.

b.         Any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of the substances referred to in paragraph 1 of this subdivision, except that these substances shall not include the isoquinoline alkaloids of opium.

c.         Opium poppy and poppy straw.

d.         Cocaine and any salt, isomer, salts of isomers, compound, derivative, or preparation thereof, or coca leaves and any salt, isomer, salts of isomers, compound, derivative, or preparation of coca leaves, or any salt, isomer, salts of isomers, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, except that the substances shall not include decocanized coca leaves or extraction of coca leaves, which extractions do not contain cocaine or ecgonine.

e.         Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid or powder form which contains the phenanthrine alkaloids of the opium poppy).

…."

SECTION 4.  G.S. 90‑91 reads as rewritten:

"§ 90‑91.  Schedule III controlled substances.

This schedule includes the controlled substances listed or to be listed by whatever official name, common or usual name, chemical name, or trade name designated. In determining that a substance comes within this schedule, the Commission shall find: a potential for abuse less than the substances listed in Schedules I and II; currently accepted medical use in the United States; and abuse may lead to moderate or low physical dependence or high psychological dependence. The following controlled substances are included in this schedule:

…

(d)       Any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or any salts thereof unless specifically exempted or listed in another schedule:

1.         Not more than 1.80 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit with an equal or greater quantity of an isoquinoline alkaloid of opium.

2.         Not more than 1.80 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

3.         Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit with a four‑fold or greater quantity of an isoquinoline alkaloid of opium.

4.         Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

5.         Not more than 1.80 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

6.         Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

7.         Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

8.         Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

9.         Buprenorphine.

…

(k)        Anabolic steroids. The term "anabolic steroid" means any drug or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progestins, and corticosteroids) that promotes muscle growth, including, but not limited to, the following:

1.         Methandrostenolone,

2.         Stanozolol,

3.         Ethylestrenol,

4.         Nandrolone phenpropionate,

5.         Nandrolone decanoate,

6.         Testosterone propionate,

7.         Chorionic gonadotropin,

8.         Boldenone,

8a.       Boldione,

9.         Chlorotestosterone (4‑chlorotestosterone),

10.       Clostebol,

11.       Dehydrochlormethyltestosterone,

11a.     Desoxymethyltesterone (17[alpha]‑methyl‑5[alpha]‑androst‑2‑en‑17[beta]‑ol) (also known as madol),

12.       Dibydrostestosterone (4‑dihydrotestosterone),

13.       Drostanolone,

14.       Fluoxymesterone,

15.       Formebulone (formebolone),

16.       Mesterolene,

17.       Methandienone,

18.       Methandranone,

19.       Methandriol,

19a.     Methasterone,

20.       Methenolene,

21.       Methyltestosterone,

22.       Mibolerone,

23.       Nandrolene,

24.       Norethandrolene,

25.       Oxandrolone,

26.       Oxymesterone,

27.       Oxymetholone,

28.       Stanolone,

29.       Testolactone,

30.       Testosterone,

31.       Trenbolone, and

31a.     19‑nor‑4, 9(10)‑androstadienedione (estra‑4, 9(10)‑diene‑3, 17‑dione), and

32.       Any salt, ester, or isomer of a drug or substance described or listed in this subsection, if that salt, ester, or isomer promotes muscle growth. Except such term does not include (i) an anabolic steroid which is expressly intended for administration through implants to cattle or other nonhuman species and which has been approved by the Secretary of Health and Human Services for such administration or (ii) chorionic gonadotropin when administered by injection for veterinary use by a licensed veterinarian or the veterinarian's designated agent. If any person prescribes, dispenses, or distributes such steroid for human use, such person shall be considered to have prescribed, dispensed, or distributed an anabolic steroid within the meaning of this subsection.

…."

SECTION 5.  G.S. 90‑92(a) reads as rewritten:

"(a)      This schedule includes the controlled substances listed or to be listed by whatever official name, common or usual name, chemical name, or trade name designated. In determining that a substance comes within this schedule, the Commission shall find: a low potential for abuse relative to the substances listed in Schedule III of this Article; currently accepted medical use in the United States; and limited physical or pyschological dependence relative to the substances listed in Schedule III of this Article. The following controlled substances are included in this schedule:

(1)        Depressants. – Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

a.         Alprazolam.

b.         Barbital.

c.         Bromazepam.

d.         Camazepam.

d1.       Carisoprodol.

e.         Chloral betaine.

f.          Chloral hydrate.

g.         Chlordiazepoxide.

h.         Clobazam.

i.          Clonazepam.

j.          Clorazepate.

k.         Clotiazepam.

l.          Cloxazolam.

m.        Delorazepam.

n.         Diazepam.

n1.       Dichloralphenazone.

o.         Estazolam.

p.         Ethchlorvynol.

q.         Ethinamate.

r.          Ethyl loflazepate.

s.          Fludiazepam.

t.          Flunitrazepam.

u.         Flurazepam.

u1.       Fospropol.

v.         Repealed by Session Laws 2000, c. 140, s. 92.2(c).

w.        Halazepam.

x.         Haloxazolam.

y.         Ketazolam.

z.         Loprazolam.

aa.        Lorazepam.

bb.       Lormetazepam.

cc.        Mebutamate.

dd.       Medazepam.

ee.        Meprobamate.

ff.        Methohexital.

gg.       Methylphenobarbital (mephobarbital).

hh.       Midazolam.

ii.         Nimetazepam.

jj.         Nitrazepam.

kk.       Nordiazepam.

ll.         Oxazepam.

mm.     Oxazolam.

nn.       Paraldehyde.

oo.       Petrichloral.

pp.       Phenobarbital.

qq.       Pinazepam.

rr.         Prazepam.

ss.        Quazepam.

tt.         Temazepam.

uu.       Tetrazepam.

uu1.     Tramadol.

vv.       Triazolam.

ww.     Zolpidem.

xx.       Zaleplon.

yy.       Zopiclone.

…

(5)        Narcotic Drugs. – Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or any salts thereof:

a.         Not not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit.

b.         Buprenorphine."

SECTION 6.  G.S. 90‑93(a) is amended by adding a new subdivision to read:

"(4)      Depressants. – Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:

a.         Ezogabine.

b.         Lacosamide."

SECTION 7.  G.S. 90‑94(3) is repealed.

SECTION 8.  This act becomes effective December 1, 2017, and applies to offenses committed on or after that date.